SAN FRANCISCO, Jan. 6, 2015 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer,
Howard W. Robin, is scheduled to
present at the upcoming 33rd Annual J.P. Morgan
Healthcare Conference in San
Francisco on Tuesday, January 13,
2015 at 11:00 a.m. Pacific
time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website: http://www.nektar.com. This Webcast will be
available for replay until February 17,
2015.
About Nektar
Nektar Therapeutics has a robust R&D pipeline in pain,
oncology, hemophilia and other therapeutic areas. In the area of
pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved
once-daily oral peripherally-acting mu-opioid receptor antagonist
(PAMORA) medication for the treatment of opioid-induced
constipation (OIC), in adult patients with chronic, non-cancer
pain. The product is also approved in the European Union as
MOVENTIG® and is indicated for adult patients with OIC who have had
an inadequate response to laxatives. The AstraZeneca agreement also
includes NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK™ and an opioid. NKTR-181, a wholly-owned
mu-opioid analgesic molecule for chronic pain conditions, has
completed Phase 2 development. NKTR-171, a wholly-owned new sodium
channel blocker being developed as an oral therapy for the
treatment of peripheral neuropathic pain, is in Phase 1 clinical
development. In oncology, NKTR-102 is being evaluated in a Phase 3
clinical study (the BEACON study) for the treatment of metastatic
breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated
Factor VIII therapeutic is in Phase 3 development conducted by
partner Baxter. In
anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by
Bayer Healthcare as an adjunctive treatment for intubated and
mechanically ventilated patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
AstraZeneca's MOVANTIK™, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
CONTACT: Jennifer Ruddock of
Nektar Therapeutics, +1-415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-33rd-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300016207.html
SOURCE Nektar Therapeutics